Cross Cancer Institute

Alberta Cancer Foundation announces $10 million in support of cellular therapy excellence

Retrieved on: 
Wednesday, October 25, 2023
Government, CAR, Government House (Alberta), Hope, Health Canada, Research, Engineering, Quality of life, Arthur Beauchesne, Clinical trial, Immune system, Radiation, Cross Cancer Institute, Immunotherapy, Cancer, Patient, Hubley, Neoplasm, Pharmaceutical industry

EDMONTON, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- At a recent BioAlberta event in Edmonton, the Alberta Cancer Foundation announced a major boost for the province’s cellular therapy program – a revolutionary treatment for cancer that has the potential to dramatically improve survival rates for hard-to-treat cancers.

Key Points: 
  • EDMONTON, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- At a recent BioAlberta event in Edmonton, the Alberta Cancer Foundation announced a major boost for the province’s cellular therapy program – a revolutionary treatment for cancer that has the potential to dramatically improve survival rates for hard-to-treat cancers.
  • “Cellular therapy may represent the most significant progress in curing some treatment-resistant cancers in decades.
  • And it’s happening right here, in Alberta,” said Wendy Beauchesne, CEO of the Alberta Cancer Foundation.
  • In 2018, the Alberta Cancer Foundation and the Government of Alberta kickstarted the Alberta Cellular Therapy Program, including a made-in-Alberta clinical trial led by the renowned Dr. Michael Chu.

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

Retrieved on: 
Friday, February 3, 2023
Gene editing, Immunotherapy, Royal College of Physicians and Surgeons of Canada, Therapy, Surgeon, University, Royal college, Bachelor, Drug development, Queen, Acquisition, Patient, Drug, Biochemistry, Cross Cancer Institute, Translation, Internal medicine, Research, Oncology, Cell, Amgen, Queen's University, Physician, Treadwell, Oklahoma Office of the Chief Medical Examiner, Roivant Sciences, Pharmaceutical industry, Eterna

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
  • Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn (now Eterna) ImmunoTherapeutics, a gene editing and cell therapy company where he advanced multiple novel programs.
  • Previously, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences.
  • Roger was also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

Retrieved on: 
Friday, February 3, 2023
Gene editing, Immunotherapy, Royal College of Physicians and Surgeons of Canada, Therapy, Surgeon, University, Royal college, Bachelor, Drug development, Queen, Acquisition, Patient, Drug, Biochemistry, Cross Cancer Institute, Translation, Internal medicine, Research, Oncology, Cell, Amgen, Queen's University, Physician, Treadwell, Oklahoma Office of the Chief Medical Examiner, Roivant Sciences, Pharmaceutical industry, Eterna

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
  • Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn (now Eterna) ImmunoTherapeutics, a gene editing and cell therapy company where he advanced multiple novel programs.
  • Previously, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences.
  • Roger was also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.

Alexander "Sandy" McEwan, MD, Joins The Bracken Groups' Expert Consultants, Deepening the Nuclear Oncology Team

Retrieved on: 
Wednesday, October 26, 2022
Radiopharmaceutical, Cross Cancer Institute, Nuclear medicine, Pleasure, University of Alberta Hospital, Diagnosis, MacEwen, Intelligence, Publication, Radiology, Consultant, University, Solution, Goal, Ipsen, Marketing, Partnership, CEO, Ecosystem, Alberta Health Services, SRT, Medical imaging, Oncology, Bracken

With over forty years of experience in oncology and nuclear medicine, Dr. McEwan is a world-renowned expert in his field.

Key Points: 
  • With over forty years of experience in oncology and nuclear medicine, Dr. McEwan is a world-renowned expert in his field.
  • As an academic physician, Dr. McEwan served as Chair of the Departments of Radiology and Oncology at the University of Alberta.
  • Dr. Colin G. Miller, CEO of Bracken, stated, "I am delighted Professor Sandy McEwan has joined The Bracken Group.
  • Through highly experienced consultative support, business programs, and data-enabled products, Bracken provides a multidisciplinary approach to exceeding goals for their clients.

Alberta Cancer Foundation Draws Winners for Cash and Cars Lottery

Retrieved on: 
Wednesday, October 19, 2022
Cross Cancer Institute, CREW, Bath, Transport, University of Calgary, Diagnosis, MINI, Patient, Strathcona County, Research, Program, Investment, Cancer, University, BMW, CEO, Alberta Health Services, Cash, COOPER, Food, AB, Pharmaceutical industry, Online gambling, Auction, Amusement arcade, Oil, Redcliff

CALGARY, AB, Oct. 19, 2022 /CNW/ - The Alberta Cancer Foundation has announced this year's winners of the Cash and Cars Lottery prizes, which include over 1,900 prizes valued at over $3.6 million.

Key Points: 
  • CALGARY, AB, Oct. 19, 2022 /CNW/ - The Alberta Cancer Foundation has announced this year's winners of the Cash and Cars Lottery prizes, which include over 1,900 prizes valued at over $3.6 million.
  • "We have had such incredible support from Albertans for the Cash and Cars lottery this year," said Wendy Beauchesne, CEO, Alberta Cancer Foundation.
  • The Alberta Cancer Foundation is the fundraising partner for the 17 Alberta Health Services cancer centres, including the Cross Cancer Institute, Tom Baker Cancer Centre and the new Calgary Cancer Centre (alongside University of Calgary).
  • To learn more about the Alberta Cancer Foundation, please visit www.albertacancer.ca
    To learn more about the Cash and Cars Lottery, please visit cashandcarslottery.ca

California Pizza Kitchen Debuts First-Ever Location in Canada

Retrieved on: 
Tuesday, July 19, 2022
Culture, California Pizza Kitchen, CPK, Facebook, News, Cancer, LinkedIn, Restaurant, Sunday, Monday, or Always, TikTok, Originality, Technology, Twitter, Cross Cancer Institute, Taste, Industry, Instagram, Growth, Breakfast sandwich, Oil, Fast food

COSTA MESA, Calif., July 19, 2022 /PRNewswire/ -- California Pizza Kitchen (CPK), the creator of California-style pizza, announced today the grand opening of its Edmonton, Alberta location, marking the brand's entry into Canada. The opening is part of the brand's latest efforts to strategically expand across target markets throughout North America, as new operators join its attractive franchise model. Located at 5260 Windermere Boulevard NW Edmonton Alberta T6Low9, the new restaurant will open its doors to the public on August 1.

Key Points: 
  • -California-fresh Pizza Concept to Open August 1st in Edmonton, Alberta-
    COSTA MESA, Calif., July 19, 2022 /PRNewswire/ -- California Pizza Kitchen (CPK), the creator of California-style pizza, announced today the grand opening of its Edmonton, Alberta location, marking the brand's entry into Canada.
  • Together, Naheed and Samira have helped successful brands grow in the Alberta region and are excited to bring California Pizza Kitchen into Edmonton.
  • "We were first introduced to California Pizza Kitchen in the mid 1990's and were immediately inspired by its culture and innovation.
  • In 1985, California Pizza Kitchen (CPK) opened its first restaurant in Beverly Hills and introduced diners to innovative California-style pizza.

BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma

Retrieved on: 
Thursday, March 3, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Liver, Cross Cancer Institute, Annual report, Lymphoid leukemia, U.S. Securities and Exchange Commission, Lymphoma, Anemia, Program, Bristol Myers Squibb, COVID-19, Disease, Medicine, Tislelizumab, Physician, Half-life, Myocardial infarction, Private Securities Litigation Reform Act, Adult, Hope, News, FDA, ORR, Company, Food, Caregiver, Atrial fibrillation, Review, Tissue, BLA, Pharmacokinetics, Death, BTK, PARP, Jazz Pharmaceuticals, MCL, Marketing, Hematology, Technology, General manager, Independent Review Committee, Global health, Novartis, NASDAQ, Form 10-K, Patient, Drug, Health Canada, Research, Twitter, WM, Safety, Goal, SSE, Diarrhea, Intellectual property, Pneumonia, Therapy, Pharmaceutical industry, Medical device, Vaccine, Fever, BeiGene, EU, myBeiGene® Patient Support Program, BRUKINSA, BeiGene, MYBEIGENE® PATIENT SUPPORT PROGRAM, BRUKINSA, BEIGENE

In clinical trials, BRUKINSA achieved a high overall response rate among relapsed/refractory MZL patients and was generally well-tolerated.

Key Points: 
  • In clinical trials, BRUKINSA achieved a high overall response rate among relapsed/refractory MZL patients and was generally well-tolerated.
  • The Health Canada marketing approval for BRUKINSA in R/R MZL is based on efficacy results from two open-label, multicenter, single arm clinical trials.
  • BRUKINSA Total Daily Dose was 320 mg daily, given as 160 mg twice daily or 320 mg once daily.
  • BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs.

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-In-Class NMT Inhibitor, in Non-Hodgkin's Lymphomas and Solid Tumor Patients

Retrieved on: 
Tuesday, September 14, 2021
Safety, BC Cancer Agency, Patient, Cross Cancer Institute, Princess Margaret Hospital, Pharmaceutical industry

Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here .

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here .
  • PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
  • Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
  • This open label, dose escalation study will examine the safety and tolerability of PCLX-001.